Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.